During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by ...

AI Innovation Unlocks Non-Surgical Way to Detect Brain Cancer Spread Jan. 14, 2025 — Researchers have developed an artificial intelligence (AI) model to detect the spread of metastatic brain ...

Jan. 16, 2025 — Scientists have made 'exciting,' patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs ... Tumor DNA in the Blood Can ...

This series of review articles published in The EMBO Journal over the course of 2021 covers a kaleidoscope of complementary aspects of tumour biology, including hypoxia, cancer evolution, the role of ...

Cervical cancer symptoms are often absent in the early stages and may only become apparent when the disease is more advanced. Abnormal vaginal bleeding is the most common symptom overall, often ...

The cancer microenvironment, or tumour microenvironment, describes the non-cancerous cells present in the tumour. These include fibroblasts, immune cells and cells that comprise the blood vessels.

Estimated numbers of new cancer cases and deaths in 2025 by cancer site and US state Current cancer incidence, mortality, and survival statistics Information on cancer symptoms, risk factors, early ...

Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use of nanoscale materials, such ...

The American Cancer Society’s estimates for primary liver cancer and intrahepatic bile duct cancer in the United States for 2025 are: About 42,240 new cases (28,220 in men and 14,020 in women) will be ...

Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2024. The list includes several groundbreaking therapies that are expected to change the ...

The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an effective first-line treatment strategy in advanced ...